Trial Profile
Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2014
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Acronyms INTREPID-OL
- Sponsors United Therapeutics Corporation
- 08 Aug 2014 New trial record
- 23 Mar 2012